Nasdaq: RETA | |
Industry | Biotechnology |
Founded | 1 January 2002 |
Fate | Acquired by Biogen |
Revenue | US $26.52 million (2019) US $53.59 million (2018)[1] |
Owner |
|
Website | www |
Reata Pharmaceuticals, Inc. is a pharmaceutical company based in Plano, Texas. Founded in 2002, it is primarily focused on investigating experimental oral antioxidative and anti-inflammatory drugs,[2] which dually activate the antioxidative transcription factor Nrf2 and inhibit the pro-inflammatory transcription factor NF-κB.[3]
In July 2023, it was announced Reata had been acquired by the Cambridge, Massachusetts-headquartered multinational biotechnology company, Biogen for nearly $6.5 billion.[4] The purchase was completed on September 26 and Reata stock was delisted from the Nasdaq.[5]